Purpose of the study
====================

The frequency and reasons for switching antiretrovirals (ARVs) in patients on a fully suppressed cART regimen (viral load \[VL\] \<50copies/ml) is not well described, nor is the effect of such a change on CD4 counts.

Methods
=======

6713 patients from EuroSIDA on cART with a confirmed VL\<50 copies/ml were included; a regimen change was defined as \>1 ARV change (occurring on the same day) for any reason whilst VL\< 50 copies/ml. Baseline was defined as the first VL\<50 copies/ml on cART; Kaplan Meier methods estimated the probability of ARV change and Cox proportional hazards models, stratified by centre, identified factors associated with ARV change. Mixed models were used to model the change in CD4 count after the first ARV change.

Results
=======

At baseline, the median CD4 was 414/mm^3^ (IQR 272---587). 1079 (16.1%) patients changed 1358 ARVs; 93 (8.6%) patients started an ARV they had previously taken. 224 (77.0%) of those starting an NNRTI (n=291) were previously naïve to NNRTIs, compared to 29 of 306 who started a PI or boosted-PI (9.5%). The incidence of changing ARVs was 11.8 per 100 PYFU (95% CI 11.1-12.5). At 1 year after baseline, 10.7% were estimated to have changed \>1 ARV (95% CI 9.8-11.5). The most common reason for change was toxicity (n=521, 38.4%), followed by patient or physician choice (n=398, 29.3%). Table [1](#T1){ref-type="table"} shows the factors associated with changing ARVs.

                                                       Multivariate               
  ----------------- ---------------------------------- -------------- ----------- ----------
                                                       RH             95% CI      P
                                                                                  
  Gender            Female versus Male                 1.29           1.09-1.53   0.0038
                                                                                  
  Risk group        Heterosexual versus other          0.83           0.70-0.98   0.033
                                                                                  
  Basline           Per year later                     1.32           1.27-1.38   \<0.0001
                                                                                  
  Nucleoside pair   Zidovudine/lamivudine              1.00           \-          \-
                                                                                  
                    Didanosine/stavudine               1.94           1.49-2.53   \<0.0001
                                                                                  
                    Stavudine/lamivudine               1.81           1.50-2.17   \<0.0001
                                                                                  
                    Tenofovir plus 1                   0.87           0.68-1.10   0.24
                                                                                  
                    Abacavir plus 1                    0.62           0.46-0.83   0.0012
                                                                                  
                    Other not listed                   1.06           0.80-1.40   0.68
                                                                                  
  Third drug        Single PI                          1.00           \-          \-
                                                                                  
                    Boosted PI                         0.46           0.36-0.58   \<0.0001
                                                                                  
                    NNRTI                              0.42           0.35-0.50   \<0.0001
                                                                                  
                    Triple nucleoside                  0.23           0.16-).35   \<0.0001
                                                                                  
  HCV serostatus    Positive versus negative/unknown   0.80           0.67-0.96   0.017

After adjustment, changing ARVs was associated with an additional annual increase in CD4 counts of 9.3/mm^3^ per year (95% CI 5.7-12.9/mm^3^) compared to not changing ARVs. The increase was similar in patients who recycled ARVs compared to those starting an ARV to which they were naive, according to type of new ARV started (nucleoside, PI, boosted-PI or NNRTI), and number of new ARVs started (0, 1 or \>2, p\>0.05 all). Patients starting a new ARV class had higher increases in CD4 counts compared to those who changed ARVs but did not start a new class (8.0/mm^3^; 95% CI 0.2-15.8/mm^3^, p=0.044), although there was no differences between PI-containing or NNRTI-containing classes (p=0.54).

Conclusions
===========

Changing ARVs whilst virologically suppressed was due to patient/physician choice or toxicity, increased in frequency over time and was more common in patients taking a single PI-regimen or in stavudine-containing regimens. Patients who changed ARVs had a small but statistically significant boost to CD4 count levels, and the increase in CD4 was higher in those who changed to a new class of ARV.
